Eli Lilly and Company (LLY) announced that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer who were randomized to receive a combination of ALIMTA with bevacizumab and carboplatin induction followed by ALIMTA plus bevacizumab maintenance-the ALIMTA arm-compared to the combination of paclitaxel with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
The study did meet one of its secondary endpoints of improved progression-free survival for the ALIMTA arm. Eli Lilly said results will be presented on September 7 at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.